Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement

Journal of Rheumatology

Volumn 34, Issue 10, 2007, Pages 2050-2055

  Nishimagi, Emi ^a   Tochimoto, Akiko ^a   Kawaguchi, Yasushi ^a   Satoh, Takashi ^b   Kuwana, Masataka ^b   Takagi, Kae ^a   Ichida, Hisae ^a   Kanno, Tokiko ^a   Soejima, Makoto ^a   Baba, Sayumi ^a   Kamatani, Naoyuki ^a   Hara, Masako ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibody; Gastrointestinal tract; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNODIFFUSION; IMMUNOPRECIPITATION; INTERSTITIAL LUNG DISEASE; JAPANESE; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; MYOSITIS; PRIORITY JOURNAL; PSEUDOOBSTRUCTION; REFLUX ESOPHAGITIS; SYSTEMIC SCLEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; FEMALE; GASTROINTESTINAL TRACT; HUMANS; JAPAN; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 35148882661     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Medsger TA Jr. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ, editor. Arthritis and allied conditions. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2001:1590-624.
2. Weinstein WM, Kadell BM. The gastrointestinal tract in systemic sclerosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004:293-308.
3. Boeckxstaens GE, Bartelsman JFWM, Lauwers L, Tytgat GNJ. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 2002;97:194-7.
4. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am 1998;27:563-94.
5. Rosson RS, Yesner R. Peroral duodenal biopsy in progressive systemic sclerosis. N Engl J Med 1965;272:391-4.
6. Greenberger NJ, Dobbins WO, Buppert RD. Intestinal atony in progressive systemic sclerosis (scleroderma). Am J Med 1968;45:301-8.
7. Malandrini A, Selvi E, Villanova M, et al. Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases. J Rheumatol 2000;27:1203-6.
8. Goldblatt F, Gordon TP, Waterman SA. Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 2002;124:1144-50.
9. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994;37:1265-82.
10. Bassotti G, Battaglia E, Debernardi V, et al. Esophageal dysfunction in scleroderma: relationship with disease subsets. Arthritis Rheum 1997;40:2252-9.
11. Wegener M, Adamek RJ, Wedmann B, Jergas M, Altmeyer P. Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci 1994;39:2209-15.
12. Weston S, Thumshirn M, Camilleri M. Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol 1998;93:1085-9.
13. Jaovisidha K, Csuka ME, Almagro UA, Soergel KH. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum 2004;34:689-702.
14. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
15. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
16. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
17. Clements PJ, Lachenbruch P, Seibold JR, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
19. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
20. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
21. Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
22. Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody. Arthritis Rheum 2005;52:2425-32.
23. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994;37:75-83.
24. Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24:323-58.
25. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.
26. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Åkesson A. The association of antibodies with organ involvement and survival in systemic sclerosis. Rheumatology Oxford 2003;42:534-40.
27. Harris ML, Rosen A. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003;15:778-84.
28. Senecal JL, Hénault J, Raymond Y. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol 200;32:1643-9.
29. Arnett FC, Reveille JD, Goldstein R, et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996;39:1151-60.
30. Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992;35:95-100.
31. Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 2004;16:723-32.
32. Satoh T, Okano T, Matsui T, et al. Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis. J Rheumatol 2005;32:1727-33.
33. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004;50:209-15.
34. Franceschini F, Cavazzana I, Generali D, et al. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J Rheumatol 2002;29:1393-7.
35. Eaker EY, Kuldau JG, Verne GN, Ross SO, Sallustio JE. Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med 1999;133:551-6.
36. Howe S, Eaker EY, Sallustio JE, Peebles C, Tan EM, Williams RC Jr. Antimyenteric neuronal antibodies in scleroderma. J Clin Invest 1994;94:761-70.
37. Reynolds JC. Immune-mediated enteric neuron dysfunction in scleroderma. J Lab Clin Med 1999;133:523-4.
38. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr. Anti-U3RNP autoantibody in systemic sclerosis (SSc): classification, demographics, clinical and laboratory features, natural history and survival in a series of 110 patients. Arthritis Rheum 2006;54Suppl:S485.
39. Kuwana M, Okano Y, Kaburaki J, Tojo T, Medsger TA Jr. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 1994;37:902-7.